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Abstract
Summary—In aging, the bone marrow fills with fat and this may lead to higher fracture risk. We 
show that a bone marrow fat measurement by magnetic resonance spectroscopy (MRS), a newer 
technique not previously studied in chronic kidney disease (CKD), is useful and reproducible. 
CKD patients have significantly higher bone marrow fat than healthy adults.
Introduction—Renal osteodystrophy leads to increased morbidity and mortality in patients with 
CKD. Traditional bone biopsy histomorphometry is used to study abnormalities in CKD, but the 
bone marrow, the source of osteoblasts, has not been well characterized in patients with CKD.
Methods—To determine the repeatability of bone marrow fat fraction assessment by MRS and 
water-fat imaging (WFI) at four sites in patients with CKD, testing was performed to determine 
the coefficients of reproducibility and intraclass coefficients (ICCs). We further determined if this 
noninvasive technique could be used to determine if there are differences in the percent bone 
marrow fat in patients with CKD compared to matched controls using paired t tests.
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Results—The mean age of subjects with CKD was 59.8±7.2 years, and the mean eGFR was 
24±8 ml/min. MRS showed good reproducibility at all sites in subjects with CKD and controls, 
with a coefficient of reproducibilities ranging from 2.4 to 13 %. MRS and WFI assessment of 
bone marrow fat showed moderate to strong agreement (ICC 0.6–0.7) at the lumbar spine, with 
poorer agreement at the iliac crest and no agreement at the tibia. The mean percent bone marrow 
fat at L2–L4 was 13.8 % (95 % CI 8.3–19.7) higher in CKD versus controls (p<0.05).
Conclusions—MRS is a useful and reproducible technique to study bone marrow fat in CKD. 
Patients with CKD have significantly higher bone marrow fat than healthy adults; the relationship 
with bone changes requires further analyses.
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Introduction
Chronic kidney disease (CKD) is an important public health problem affecting more than 26 
million Americans. Fractures are two to four times more prevalent in patients with CKD 
compared to the general population [1, 2]. Renal osteodystrophy, an abnormal bone 
histomorphometry associated with CKD, is one component of CKD-mineral bone disorder 
(CKD-MBD) and is associated with significant morbidity [3–6]. In patients with renal 
osteodystrophy, there are extremes of histomorphometric findings—from high bone 
formation rates secondary to hyperparathyroidism where there is increased osteoblast and 
osteoclast cell numbers to adynamic bone disease with low bone formation rates and a 
paucity of cells. These extremes in bone remodeling also make a bone architecture different 
in healthy controls and make noninvasive diagnosis a challenge [7]. Currently, the gold 
standard diagnosis for renal osteodystrophy is bone biopsy. However, not all facilities have 
such capabilities, leading to the development of techniques that may offer an alternative to 
either bone biopsy or biomarkers. Similar to the need to validate circulating biomarkers, it is 
important to examine the reproducibility of new bone imaging techniques specifically in 
CKD patients prior to use in research or for clinical care.
CKD patients have a phenotype of premature aging with increased cardiovascular, fall, and 
fracture risk [8–10]. In the general population, there is an increase in bone marrow fat 
content with advanced age [11] and this correlates with decreased bone mineral density [12, 
13]. Adipocytes and osteoblasts arise from common cellular precursors, mesenchymal stem 
cells (MSCs), suggesting that the preferential differentiation towards adipocyte lineage, 
assessed by increased bone marrow fat, may alter osteoblast differentiation from 
mesenchymal stem cells. Bone marrow fat can be quantified by magnetic resonance 
spectroscopy (MRS), which utilizes the resonance frequency of protons to differentiate fat 
from water; the ratio provides an assessment of chemical composition of bone marrow [14]. 
In animal studies, the volume of bone marrow fat by biopsy strongly correlates (r=0.9) with 
fat volume assessed by MRS [15]. MRS is currently used for quantifying the bone marrow 
fat in the normal population, with lumbar spine being the most studied site [16].
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Bone marrow fat content can be also measured using water-fat imaging (WFI) methods such 
as the three-point Dixon method which covers a large area of bone and is more cost-
effective than MRS [14]; therefore, we compared the reproducibility or the two techniques 
for the assessment of bone marrow fat content and whether there were differences in 
subjects with CKD compared to controls.
Methods
The study had four objectives: (1) to determine the reproducibility of bone marrow fat 
assessment by MRS in CKD subjects, (2) to determine if the bone marrow fat percentage in 
CKD patients is different at various skeletal sites (lumbar L2–L4 vertebrae, posterior iliac 
crest (the site of bone biopsy used to diagnose renal osteodystrophy), and tibia) (3) to 
compare the bone marrow fat assessment by MRS and using WFI-based technique (three-
point Dixon method) at the above skeletal sites, and (4) to compare the percent bone marrow 
fat in CKD subjects to that in matched controls with normal kidney function at the lumbar 
vertebrae, the standard site for MRS, in a pilot study.
Inclusion/exclusion criteria
CKD subjects were recruited from the clinics at Indiana University. Inclusion criteria were 
age ≥45 years old, estimated GFR±45 ml/min/1.732 m2 using the four-parameter MDRD 
formula in the last 6 months, and elevated PTH above the normal range (±65 pg/ml) in the 
past year, confirming a diagnosis of CKD-MBD. Exclusion criteria were females who were 
pregnant or nursing, a prior history of tibial or lumbar fracture, general contraindications to 
MRI/MRS exam (e.g., IUD, pacemaker), bilateral lower extremity amputation, history of 
hematological malignancy, chemotherapy or radiation therapy, institutionalized, or unable to 
give consent. The healthy control participants were subsequently recruited from a 
centralized volunteer registry. They were matched for race, gender, and age ±10 years to the 
CKD subjects. All participants, both CKD subjects and controls, provided written informed 
consent, and all study procedures were approved by the Institutional Review Board at 
Indiana University School of Medicine.
Study procedures
For the intrapatient variability assessments, the first five CKD subjects and five controls 
underwent two MRS and WFI scans of the lumbar vertebrae, iliac crest, and tibia with 
repositioning between measurements. MRS of L2 to 4 vertebrae was performed in additional 
five subjects; after interim analyses, it was demonstrated that the lumbar spine was the most 
reproducible site. All subjects underwent a blood draw at the time of their MRS scan. The 
blood was collected, stored at −80 °C, and batch analyzed for intact PTH (ALPCO, Salem, 
NH). GFR was taken from the last clinically available assessment, all within the last 6 
months.
Detailed imaging methods
Protons in water and fat molecules are subjected to different chemical environments. They 
produce signals with slightly different frequencies. If measured with a spectroscopy 
technique at 3 tesla, fat and water signal peaks are separated by about 440 Hz. If measured 
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with multi-echo gradient echo techniques, the phase shift difference between fat and water is 
modulated by the delay of acquisition from the initial excitation or the echo time (TE). By 
modeling signal behavior with respect to TE, the ratio of fat and water signal can be 
determined. Such technique for WFI is known as the Dixon technique [14].
All MR examinations of the lumbar spine, iliac crest, and tibia (junction of upper one third 
and lower two thirds) were performed on a 3-T clinical MRI scanner (Magnetom TIM Trio; 
Siemens Medical Systems, Erlangen, Germany) using a phased array spine coil. Subjects 
were in supine position with knees supported by a form wedge to reduce spine curvature and 
motion by improving patient comfort. After initial localization, single-voxel MRS and three-
point Dixon scans were performed on the L2–L4 lumbar vertebrae, iliac crest, and tibia to 
quantify the fat fraction of bone marrow.
To determine the MRS measurement of percent bone marrow fat, multiple proton (1H) 
spectra of TE=12, 24, 36, 48, and 72 ms and repetition time (TR)=4 s were acquired with 
stimulated echo acquisition method (STEAM) from a 10×10×10 mm3 voxel in the center of 
the marrow region for each site. The signal intensity of water and fat peaks was quantified at 
each TE by integrating the corresponding spectral region. The fat% was calculated from the 
water and fat signal intensities after correction for T2 decay by fitting an exponential 
function to the signal change with TE as shown in Fig. 1. To determine the WFI 
measurement of percent bone marrow fat, a 3D multi-echo spoiled fast gradient echo 
sequence was used to acquire data at three TEs=2.46, 3.67, and 7.35 ms and TR= 10 ms. For 
the lumbar spine, a sagittal slab consists of 32 slices of 4 mm in thickness and a 25-cm field 
of view (FOV) was used to cover the entire lumbar spine. The acquisition matrix size was 
256×192, and the flip angle (FA) was 15°. For the iliac crest and tibia, a transverse slab of 
32 slices of 2 mm in thickness was used. The FOV and matrix size were 35 cm and 256×192 
for the iliac crest and 17 cm and 128×102 for the tibia, respectively. Using the Dixon fat and 
water separation technique, corresponding fat-only, water-only, and fat fraction images were 
also generated. The 3D fat fraction images with thin slices were formatted to 10-mm slices 
to improve the signal-to-noise ratio (SNR). Regions of interest (ROIs) of 10×10 mm2 were 
then placed in the center of the L2, L3, and L4 lumbar vertebrae, right iliac crest, or right 
tibia on the reformatted fat fraction image to obtain the average fat percentage of the bone 
marrow.
Statistical analysis
We enrolled ten CKD subjects and controls, but due to technical difficulties in scans of one 
subject and one control scan, only a total of eight pairs of scans could be used in the 
analysis. The coefficient of repeatability for percent bone marrow fat at each site by MRS 
and WFI was calculated. The coefficient of repeatability (COR) represents the value under 
which the difference between any two repeat measures on the same patient acquired under 
identical conditions should fall with 95 % probability [17]. Inter-method intraclass 
coefficients (ICCs) were calculated at each site and used to compare marrow fat content 
assessment by WFI and MRS at different skeletal sites. The ICC is the ratio of the between-
method variation to the total variation [18]; higher ICCs (range from 0 to 1) represent better 
repeatability or agreement. Pearson’s correlations also were calculated to compare the bone 
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marrow fat percentage at each site between WFI and MRS. Paired t tests were used to 
compare the percent bone marrow fat between the eight CKD subjects and controls at the 
lumbar sites. Results are expressed as mean±SD. A 5 % significance level was used for 
statistical tests. Analyses were performed using SigmaPlot (SigmaPlot, Chicago, IL) and 
SAS version 9.3 (SAS Institute, Cary, NC).
Results
Among the eight CKD subjects, five were female. Two subjects were African-American, 
and the majority (five subjects) were diabetic. The mean age of subjects in the study was 
59.8±7.2 years, and mean eGFR was 24±8 ml/min/1.732 m2 (Table 1). The mean age of 
controls was 58.1±10.2 years, and each CKD patient-control pair was matched according to 
race and gender, as per the protocol. The mean body mass index (BMI) of subjects was 
31.3+7.6 kg/m2 and was not significantly different from the mean BMI of controls (27.6 
±4.7 kg/m2, p=0.28). MRS showed good reproducibility at all sites in subjects with CKD 
and controls, including at the iliac crest with COR values ranging from 2.4 to 13 %. The 
tibia site, with the percent bone marrow fat greater than 80 %, offered the highest 
reproducibility (Table 2). MRS and WFI assessment of bone marrow fat showed moderate 
to strong agreement (ICC 0.6–0.7) at the lumbar sites, with poorer agreement at the iliac 
crest and no agreement at the tibia (Table 3). Pearson’s correlations for bone marrow fat 
percentage at L2, L3, and L4 by MRS versus MRI were 0.78 (p= 0.007), 0.83 (p=0.002), 
and 0.79 (p=0.007), respectively.
The mean bone percent marrow fat at L2 was 57.8±12.2 % in subjects with CKD versus 
41.7±10.8 % in controls (p= 0.02). At L3, the bone marrow fat percentage was 56.9± 11.1 % 
in CKD versus 44.8±11.4 % in controls (p=0.02). Similarly, at L4, the percent bone marrow 
fat was 59.8±10.1 % versus 46.3±11.6 % (p=0.03) (Fig. 2). There was no significant 
correlation with PTH and the bone marrow fat percentage for either group. Similarly, there 
was no significant correlation of the BMI and the bone marrow fat percentage for either 
group with the exception of the L2 region in the control group.
Discussion
In the present study, we compared single-voxel MRS to three-point Dixon WFI techniques 
for the assessment of bone marrow fat at multiple sites in patients with CKD. The results 
showed comparable variability in subjects with CKD compared to controls. MRS has high 
spectral resolution which ideally allows more complete fat and water separation and low 
spatial resolution because of its large voxel size. However, MRS is sensitive to various 
system imperfections which can distort the spectral peaks and baseline, causing 
quantification errors. In addition, MRS measurement is performed at a finite echo time (TE) 
which causes the results to be T2 weighted. While the T2 weighting can be corrected by 
extrapolating results obtained at multiple TEs, this process inevitably introduces an 
additional error. WFI, on the other hand, has much higher spatial resolution, but low spectral 
resolution. Its fat and water separation may not be accurate, especially when the spectral 
peak is more complicated with several overlapping smaller peaks. The Dixon technique also 
requires phase unwrapping, which sometimes does not work reliably, especially in regions 
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of high magnetic field inhomogeneity. The main advantages of the MRI (WFI) technique are 
its efficiency and flexibility. A large region can be covered with a high resolution 3D 
acquisition. The fat fraction at multiple locations can be measured with retrospectively user-
defined ROIs anywhere in the imaging volume. The single-voxel MRS technique, however, 
only produces the fat fraction from a single predetermined voxel. Previous studies in healthy 
populations assessing the lumbar spine showed Pearson’s correlations of 0.79 and 0.85 
between the MRS and the Dixon technique [19, 20], similar to the correlation coefficients 
between 0.78 and 0.83 at L2–L4 between these two methods in our CKD subjects. However, 
the ICC is a superior method for assessing the agreement between methods, and in our 
study, the ICC of MRS compared to WFI for the assessment of bone marrow fat at the 
lumbar spine was reasonable (0.6–0.7), but not perfect. The results were poor for the iliac 
crest and tibia. This may reflect a heterogeneity of marrow fat content in different bones. 
Autopsy studies demonstrated the increased marrow fat deposition with aging occurs 
diffusely throughout the skeleton, although the proportion of fat replacement of the marrow 
varies at different skeletal sites [21]. Based on our studies in CKD subjects, we conclude 
that MRS is the preferable technique to detect the percent bone marrow fat and that the 
lumbar spine is the most reliable site for marrow fat measurements.
In subjects with CKD, we found that the bone marrow fat content assessed by MRS was 
13.8 % (95 % CI 8.3–19.7) higher at L2–L4 compared to matched controls. The key 
limitations of our study were small sample size as well as the lack of a gold standard 
assessment of bone and adipose content of marrow such as could be obtained by a bone 
biopsy. However, despite the limited sample size in this pilot study, the difference of 13.8 % 
in lumbar bone marrow fat was significant. Griffiths et al. showed that the difference in bone 
marrow fat at the L2 vertebra by MRS between 17 osteoporotic males and 42 control 
participants with normal bone density was 7.78±7.8 % [22]. In the aging general population, 
the bone marrow fat by MRS correlates well with osteopenia and osteoporosis by DXA and 
vertebral fractures [12, 22, 23]. Although we did not performed bone density or fracture 
assessments, based on studies in the aging population, the 13.8 % difference in bone marrow 
fat percentage in patients with CKD compared to controls observed in the present study is 
likely clinically significant. Future studies are needed to study the bone marrow in 
conjunction with bone density, volume, and histomorphometric changes in humans with 
CKD.
Aging is associated with significantly increased adipogenesis in the bone marrow on iliac 
crest biopsies, and this increased adipocyte fraction was found to be inversely correlated 
with the trabecular bone volume [11, 21, 24]. With aging, there is a fat replacement of the 
vertebral marrow that is disproportionate to the loss of hematopoietic elements, leading to 
net marrow fat accumulation [24]. The similarities of these studies and our observation of 
increased marrow adipogenesis in CKD suggest that alterations of marrow composition may 
be another manifestation of the premature aging of CKD. The cause of increased 
adipogenesis in CKD and aging is unknown. In the past, adiposity was assumed to be 
secondary to fat simply “filling the holes left by trabecular loss” and thus a consequence 
rather than a cause of bone loss. However, more recent studies have found that adipogenesis 
in the marrow may inhibit osteoblast formation and/or increase osteoclastic activity due to 
both abnormal differentiation and impaired bone marrow niche [25, 26]. Understanding 
Moorthi et al. Page 6
Osteoporos Int. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
these mechanisms may identify the role of modulators of marrow adiposity to improve bone 
outcomes [26].
Patients with CKD have a wide range of findings on bone biopsy and high fracture rates [27, 
28]. Over the years, the diagnosis and management of renal osteodystrophy has been 
focused on bone formation rates, as PTH was considered as the primary etiology of bone 
abnormalities in CKD. However, despite years of lowering PTH, a fracture risk has not 
substantially changed [29]. Furthermore, fractures in CKD are associated with both low and 
high levels of PTH [30, 31]. Therefore, there is a need to understand the importance of non-
PTH-mediated effects on the bone [32]. In the present study, we found increased fat 
adiposity in the bone marrow of patients with CKD compared to age-, sex-, and race-
matched controls. Whether this leads to an abnormal MSC cell number of differentiation is 
unknown. Further studies correlating these observations with bone biopsy in patients with 
CKD are warranted. The results of the present study demonstrate that MRS is a reproducible 
technique to study changes in bone marrow fat, facilitating the conduct of such studies.
Conclusions
Bone marrow fat assessment by MRS remains to be the best available technique to study 
changes in bone marrow fat at various skeletal sites in CKD patients, with the lumbar spine 
being the most reproducible site. We further demonstrated that the percentage of marrow 
adiposity is higher in the lumbar spine of those with moderate to late stage CKD compared 
to those with normal kidney function. The bone consequences of this increased adiposity in 
the marrow of CKD patients require further study.
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Fig. 1. 
MRS assessment of bone marrow fat. a The circles within the lumbar spine body on MRI 
image are the regions of interest (10×10×10 mm3 voxels in the bone marrow region). Within 
each region, the T2-weighted proton spectra of TE=12, 24, 36, 48, and 72 ms and TR=4 s 
were acquired with STEAM techniques. b The signal intensity of water and fat peaks were 
quantified at each TE. The fat% was calculated from the T2-corrected water and fat signal 
intensities
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Fig. 2. 
Percent bone marrow fat by MRS in CKD patients compared to controls. CKD subjects 
(black bars) were compared to age-, race-, and gender-matched controls (gray bars) for 
MRS at L2, L3, and L4 sites (eight matched pairs, total N=16). At each site, the percent 
bone marrow fat in patients with CKD was less than that in control subjects, p<0.05
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Table 2
Marrow fat% at different sites in CKD patients and controls by MRS and coefficients of repeatability
Skeletal site CKD patients (n =5) Controls (n=5)
Mean±SD (%) COR (%)a Mean±SD (%) COR (%)a
L2 58.1±11.0 13 47.1±8.6 4.9
L3 58.6±10.2 6.1 51.0±6.7 4.7
L4 61.0±11.0 3.4 51.8±9.5 6.6
Iliac crest 59.4±14.6 5.5 52.4±8.5 7.1
Tibia 86.4±1.5 2.4 84.8±2.6 3.8
aCOR=coefficient of repeatability is the value under which the difference between any two repeat measurements on the same patient acquired 
under identical conditions should fall with 95 % probability
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Table 3
Comparison of MRS and WFI for bone marrow fat quantification using inter-method intraclass coefficients
Skeletal site Inter-method ICC CKD
Overall Controls
L2 0.705 0.607 0.606
L3 0.674 0.482 0.696
L4 0.694 0.497 0.736
Iliac crest 0.285 0.083 0.330
Tibia 0.038 0.069 0
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